Ibrutinib and Stroke - a phase IV clinical study of FDA data

Summary:

Stroke is reported as a side effect among people who take Ibrutinib (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Norvasc, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Stroke when taking Ibrutinib. It is created by eHealthMe based on reports of 13,522 people who have side effects when taking Ibrutinib from the FDA, and is updated regularly.

What is Ibrutinib?

Ibrutinib has active ingredients of ibrutinib. eHealthMe is studying from 13,529 Ibrutinib users. Check the latest studies of Ibrutinib.

What is Stroke?

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen) is found to be associated with 2,330 drugs and 3,028 conditions by eHealthMe. Check the latest studies of Stroke.

On Jun, 23, 2026

13,522 people reported to have side effects when taking Ibrutinib.
Among them, 85 people (0.63%) have Stroke.

Among these 85 people:

How long have people been on Ibrutinib when they have Stroke? *

What is the gender of people who have Stroke when taking Ibrutinib? *

female: 33.87 %
male: 66.13 %

What is the age of people who have Stroke when taking Ibrutinib? *

What are other drugs people take besides Ibrutinib? *

What are other side effects people have besides Stroke? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 20 people, 23.53%
Pneumonia: 15 people, 17.65%
Heart Attack: 12 people, 14.12%
Haemorrhage (bleeding): 9 people, 10.59%
Infection: 7 people, 8.24%
Thrombocytopenia (decrease of platelets in blood): 7 people, 8.24%
Diarrhea: 6 people, 7.06%
Acute Kidney Failure: 6 people, 7.06%
Cardiac Failure: 6 people, 7.06%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 6 people, 7.06%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 47 people, 55.29%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 14 people, 16.47%
High Blood Pressure: 7 people, 8.24%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 7.06%
Lymphoma (cancer that begins in immune system cells): 5 people, 5.88%
Multiple Myeloma (cancer of the plasma cells): 5 people, 5.88%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 4.71%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 4 people, 4.71%
Diabetes: 4 people, 4.71%
Fungal Infection: 3 people, 3.53%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrutinib and have Stroke?

- Check whether Stroke is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrutinib:

Ibrutinib (13,529 reports)

Stroke treatments and more:

Stroke (334,635 reports)

Browse all side effects of Ibrutinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Stroke:

Stroke (2,330 drugs)

Browse all the conditions that are associated with Stroke:

Stroke (3,028 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Ibrutinib) and Ibrutinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.